Empirical Vancomycin — Competitive Intelligence Brief

Empirical Vancomycin (Empirical Vancomycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycopeptide antibiotic. Area: Infectious Disease / Oncology (supportive care in cancer patients).

phase 3 Glycopeptide antibiotic Bacterial peptidoglycan (D-Ala-D-Ala) Infectious Disease / Oncology (supportive care in cancer patients) Small molecule

Target snapshot

Empirical Vancomycin (Empirical Vancomycin) — Memorial Sloan Kettering Cancer Center. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Empirical Vancomycin TARGET	Empirical Vancomycin	Memorial Sloan Kettering Cancer Center	phase 3	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Prophylactic Vancomycin	Prophylactic Vancomycin	Memorial Sloan Kettering Cancer Center	phase 3	Glycopeptide antibiotic	Bacterial peptidoglycan D-Ala-D-Ala precursors
Aerosolized Tobramycin or Vancomycin	Aerosolized Tobramycin or Vancomycin	Wright State University	marketed	Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin)	Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin)
Vancomycin intermittent dosing interval	Vancomycin intermittent dosing interval	Massachusetts General Hospital	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Administration of Vancomycin	Administration of Vancomycin	University of Colorado, Denver	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Vancomycin - model-based dosing regimen	Vancomycin - model-based dosing regimen	Murdoch Childrens Research Institute	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Teicoplanin antimicrobial-lock solution	Teicoplanin antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycopeptide antibiotic class)

1. Clinica Universidad de Navarra, Universidad de Navarra · 2 drugs in this class
2. Memorial Sloan Kettering Cancer Center · 2 drugs in this class
3. Wake Forest University Health Sciences · 2 drugs in this class
4. VA Office of Research and Development · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Murdoch Childrens Research Institute · 1 drug in this class
7. OrthoCarolina Research Institute, Inc. · 1 drug in this class
8. University of Colorado, Denver · 1 drug in this class
9. University of Maryland, Baltimore · 1 drug in this class
10. Debiopharm International SA · 1 drug in this class